Company Profile

Forecyte Bio Limited is a CDMO company founded in 2021 to service the rapidly growing Cell and Gene Therapy (CGT) industry. Built on decades of experience and expertise from its core technical experts on CGT CMC processes,

Forecyte Bio offers a “one-stop” holistic service package to accelerate clients’ projects from early concept to IND filing and eventual commercial licensure and manufacturing. With our unique value-added model, we work closely with clients to provide early process development/optimization, preparation of CMC documentations for regulatory filings such as IND, clinical manufacturing, support for BLA filing and commercial manufacturing for a wide range of CGT products including  plasmids, viral vectors such as Adeno-associated virus (AAV), Adenovirus (AdV), Lentivirus (LV), Oncolytic virus (OV), and Retrovirus (RV) , as well as cell products (CAR-T, TCR-T, CAR-NK).  

Our facilities in US and China both offer process development and GMP production capabilities to provide coherent services for clients looking for multi-national studies.